SAR and evaluation of novel 5H-benzo[c][1,8]naphthyridin-6-one analogs as Aurora kinase inhibitors

Bioorg Med Chem Lett. 2013 May 15;23(10):3081-7. doi: 10.1016/j.bmcl.2013.03.008. Epub 2013 Mar 13.

Abstract

Several potent Aurora kinase inhibitors derived from 5H-benzo[c][1,8]naphthyridin-6-one scaffold were identified. A crystal structure of Aurora kinase A in complex with an initial hit revealed a binding mode of the inhibitor within the ATP binding site and provided insight for structure-guided compound optimization. Subsequent SAR campaign provided a potent and selective pan Aurora inhibitor, which demonstrated potent target modulation and antiproliferative effects in the pancreatic cell line, MIAPaCa-2. Furthermore, this compound inhibited phosphorylation of histone H3 (pHH3) in mouse bone morrow upon oral administration, which is consistent with inhibition of Aurora kinase B activity.

MeSH terms

  • Administration, Oral
  • Animals
  • Aurora Kinases / antagonists & inhibitors*
  • Aurora Kinases / metabolism
  • Cell Line, Tumor
  • Crystallography, X-Ray
  • Dose-Response Relationship, Drug
  • Histones / antagonists & inhibitors
  • Histones / metabolism
  • Humans
  • Mice
  • Models, Molecular
  • Molecular Structure
  • Naphthyridines / administration & dosage
  • Naphthyridines / chemical synthesis
  • Naphthyridines / pharmacology*
  • Phosphorylation / drug effects
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / chemical synthesis
  • Protein Kinase Inhibitors / pharmacology*
  • Structure-Activity Relationship

Substances

  • 5H-benzo(c)(1,8)naphthyridin-6-one
  • Histones
  • Naphthyridines
  • Protein Kinase Inhibitors
  • Aurora Kinases